Biosyent Inc (TSE:RX)
TSXV:RX
Canadian Market

Biosyent (RX) Cash flow

40 Followers

Biosyent Cash Flow

TSE:RX's free cash flow for Q4 2023 was C$622.65K. For the 2023 fiscal year, TSE:RX's free cash flow was decreased by C$451.31K and operating cash flow was C$674.99K. See a summary of the company’s cash flow.
Cash Flow
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Operating Cash Flow
C$ 5.05MC$ 5.05MC$ 4.95MC$ 4.67MC$ 6.89MC$ 4.40M
Investing Cash Flow
C$ 883.85KC$ 883.85KC$ -10.79MC$ -4.84MC$ 3.39MC$ -1.32M
Financing Cash Flow
C$ -5.78MC$ -5.78MC$ -4.37MC$ -2.08MC$ -3.37MC$ -6.39M
Cash Flow From Discontinued Operation
------
Other Cash Adjustment Inside Changein Cash
------
End Cash Position
C$ 33.37MC$ 7.98MC$ 7.86MC$ 18.04MC$ 20.29MC$ 13.44M
Income Tax Paid Supplemental Data
--C$ -1.76MC$ 2.32MC$ 1.37MC$ 1.92M
Interest Paid Supplemental Data
------
Issuance Of Capital Stock
------
Issuance Of Debt
C$ -1.01MC$ -617.53KC$ -161.81KC$ -151.95K--
Repayment Of Debt
C$ -1.01MC$ -617.53KC$ -161.81KC$ -151.95KC$ -144.25KC$ -23.28K
Free Cash Flow
C$ 4.88MC$ 4.88MC$ 4.43MC$ 4.67MC$ 6.72MC$ 3.67M
Domestic Sales
------
Foreign Sales
------
Currency in CAD

Biosyent Cash Flow

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis